Videos

AGTC XLRS Platform Well Tolerated

By Mario Admin | November 15, 2016

Early reports of AGTC’s lead gene therapy program for X-linked retinoschisis have shown the treatment to be well-tolerated with only mild-to-moderate inflammation that either resolves…

Read More
aura-biosciences

Aura Biosciences on Track for 2017 IND

By Mario Admin | November 15, 2016

Aura Biosciences expects to have an active investigational new drug (IND) application for its first-in-class treatment for primary choroidal melanoma early next year and have…

Read More

Adverum Biotechnologies Gains Momentum in Gene Therapy

By Mario Admin | November 14, 2016

CHICAGO—Adverum is a gene therapy company “committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or…

Read More

Triggerfish: Contact Lens-based Glaucoma Solution

By Jackie Wengrod | November 14, 2016

Sensimed’s Triggerfish is the “first ever Food and Drug Administration-approved contact lens sensor,” said David Bailey, chief executive officer. The lens received US approval in…

Read More

AcuFocus: More Than Just the KAMRA

By Jackie Wengrod | November 14, 2016

Small aperture technology is the only corneal-based presbyopia-correcting procedure that does not rely on the use of “plus power” in the cornea to provide near…

Read More
revision-optics

ReVision Optics Rolling Out Raindrops Following FDA OK

By Jackie Wengrod | November 14, 2016

The Raindrop Near Vision Inlay for the treatment of presbyopia boasts a 2 mm diameter, 80% water composition, the same refractive index as the natural…

Read More

SightLife Surgical Hopes to Help Corneal Patients

By Jackie Wengrod | November 14, 2016

Corneal blindness remains a “significant and growing problem,” said Monty Montoya, chief executive officer, SightLife Surgical. There are more than 10 million corneal blind who…

Read More

LacriPen: A Portable Lab in Your Hands

By Jackie Wengrod | November 14, 2016

Osmolarity is the one biophysical measurement that “can reliably diagnose dry eye disease (DED) initially and follow the therapeutic response secondarily, said Chris Geddes, PhD,…

Read More

TearScience: Improving Dry Eye Outcomes

By Jackie Wengrod | November 14, 2016

What if there was a therapy that could cut dry eye disease (DED) symptoms in half, improve tear secretion three-fold, and be sustainable for a…

Read More

Innovative Financing Opportunities: What They’re Looking For

By Mario Admin | November 11, 2016

For early medtech players in ophthalmology, making connections for start-up capital can be a challenging task, but at the session “Innovative Financing Options in Ophthalmology”…

Read More

Ivantis: Making Waves in the MIGS Space

By Jackie Wengrod | November 11, 2016

Ivantis is developing “the only minimally invasive microstent for glaucoma that dilates and reconstructs the primary outflow path of the eye,” said president and chief…

Read More

Envisia Therapeutics: Overcoming Compliance Issues in Glaucoma

By Jackie Wengrod | November 11, 2016

Compliance with topical medication drops to manage glaucoma “is horrid,” said Benjamin Yerxa, PhD, co-founder and president, Envisia Therapeutics. Poor compliance results in disease progression,…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.